Cancer of unknown primary—state of the art
Tóm tắt
Từ khóa
Tài liệu tham khảo
Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(3):228–46. https://doi.org/10.1016/j.annonc.2022.11.013.
Kolling S, Ventre F, Geuna E, et al. “Metastatic cancer of unknown primary” or “primary metastatic cancer”? Front Oncol. 2019;9:1546. https://doi.org/10.3389/fonc.2019.01546.
Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 2019;61:139–41. https://doi.org/10.1016/j.canep.2019.06.006.
Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020;17(9):541–54. https://doi.org/10.1038/s41571-020-0359-1.
NCCN clinical practice guidelines in oncology: occult primary.. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf..
CUP Syndrom – Krebserkrankungen mit unbekanntem Primärtumor.. https://www.onkopedia.com/de/onkopedia/guidelines/cup-syndrom-krebserkrankungen-mit-unbekanntem-primaertumor/@@guideline/html/index.html..
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19(3):731–44. https://doi.org/10.1007/s00330-008-1194-4.
Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43(14):2026–36. https://doi.org/10.1016/j.ejca.2007.06.023.
Karim Fizazi A. A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site. ESMO https://doi.org/10.1093/annonc/mdz394.
Lee MS, Sanoff HK. Cancer of unknown primary. BMJ. 2020;371:m4050. https://doi.org/10.1136/bmj.m4050.
Gatalica Z, Xiu J, Swensen J, Vranic S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer. 2018;94:179–86. https://doi.org/10.1016/j.ejca.2018.02.021.
Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895–902. https://doi.org/10.1093/annonc/mdy263.
Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35(7):570–3. https://doi.org/10.1016/j.ctrv.2009.05.005.